Literature DB >> 9299365

Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex.

E H Herman1, J Zhang, B B Hasinoff, J R Clark, V J Ferrans.   

Abstract

Histologic, nick end labeling for apoptosis and electron microscopic studies were made of the heart, kidney and small intestine in spontaneously hypertensive rats (SHR) treated for 12 weeks with doxorubicin (1 mg/kg/week), mitoxantrone (0.5 or 0.25 mg/kg/week) or saline (controls). Semiquantitative scoring showed that the severity of the cardiac lesions produced by doxorubicin was comparable to that resulting from 0.5 mg/kg mitoxantrone, but greater than that induced by 0.25 mg/kg mitoxantrone (to which it is therapeutically equivalent). The nephropathy and the intestinal toxicity produced by doxorubicin were also more severe than those resulting from either dose of mitoxantrone. Apoptosis of cardiac myocytes was not induced by either drug, but involved cardiac dendritic cells in SHR given doxorubicin. Apoptosis in renal tubular epithelium was comparable in SHR given doxorubicin and the higher dose of mitoxantrone. Doxorubicin induced more frequent apoptosis in intestinal epithelium than did the higher dose of mitoxantrone. We also show that mitoxantrone and iron(III) form a strong 2:1 complex, in which the drug may be acting as a tridentate ligand. This complex, like the iron(III)-doxorubicin complex, may be capable of redox cycling and producing reactive oxygen intermediates (ROI) that damage tissue. Decreased formation of ROI by mitoxantrone may account for its reduced cardiotoxicity compared to that of doxorubicin. Copyright 1997 Academic Press Limited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299365     DOI: 10.1006/jmcc.1997.0477

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  11 in total

Review 1.  Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Authors:  D Jain
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

2.  Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides.

Authors:  M El Mouedden; G Laurent; M P Mingeot-Leclercq; H S Taper; J Cumps; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

Authors:  Sophie Goffette; Vincent van Pesch; Jean Louis Vanoverschelde; Emmanuel Morandini; Christian J M Sindic
Journal:  J Neurol       Date:  2005-04-18       Impact factor: 4.849

4.  Effects of mitoxantrone on action potential and membrane currents in isolated cardiac myocytes.

Authors:  G X Wang; X B Zhou; T Eschenhagen; M Korth
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 5.  Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Authors:  Danielle Harake; Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Future Cardiol       Date:  2012-07

6.  Application of Fenton, photo-Fenton, solar photo-Fenton, and UV/H2O2 to degradation of the antineoplastic agent mitoxantrone and toxicological evaluation.

Authors:  Rodrigo Pereira Cavalcante; Lucas da Rocha Sandim; Danielle Bogo; Antônio Marcos Jacques Barbosa; Marly Eiko Osugi; Matildes Blanco; Silvio Cesar de Oliveira; Maria de Fatima Cepa Matos; Amilcar Machulek; Valdir Souza Ferreira
Journal:  Environ Sci Pollut Res Int       Date:  2012-08-12       Impact factor: 4.223

7.  Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.

Authors:  Shashi Raj; Vivian I Franco; Steven E Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

8.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

9.  Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells.

Authors:  Ana Reis-Mendes; Marisa Alves; Félix Carvalho; Fernando Remião; Maria Lourdes Bastos; Vera Marisa Costa
Journal:  Interdiscip Toxicol       Date:  2018-08-06

10.  Doxorubicin induces large-scale and differential H2A and H2B redistribution in live cells.

Authors:  Péter Nánási; László Imre; Erfaneh Firouzi Niaki; Rosevalentine Bosire; Gábor Mocsár; Anett Türk-Mázló; Juan Ausio; Gábor Szabó
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.